Published in Lancet on March 03, 1979
Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.02
Perineal talc use and ovarian cancer: a critical review. Eur J Cancer Prev (2008) 0.91
Effects of talc on the rat ovary. Br J Exp Pathol (1984) 0.82
Over-the-counter treatments and perineal hygiene in postmenopausal women. Menopause (2014) 0.75
A prognostic index in primary breast cancer. Br J Cancer (1982) 7.35
AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A (1992) 5.24
Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res (1985) 5.09
Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol (1986) 4.75
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A (1992) 3.22
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res (1987) 2.67
Relationship of oestrogen-receptor status to survival in breast cancer. Lancet (1979) 2.55
Relationship between primary breast tumor receptor status and patient survival. Cancer (1980) 2.49
Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science (1984) 2.24
Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst (1996) 2.17
Oestrogen receptors and survival in early breast cancer. Br Med J (Clin Res Ed) (1981) 2.14
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res (1978) 1.95
Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer (1978) 1.90
Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol (1985) 1.86
Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol (1991) 1.83
Oestrogen receptors and prognosis in early breast cancer. Lancet (1979) 1.83
Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst (1992) 1.82
BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models. J Cardiovasc Pharmacol (1986) 1.79
Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer (1996) 1.71
Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1985) 1.67
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst (1992) 1.61
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res (1998) 1.61
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol (2000) 1.58
Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res (1988) 1.55
Inhibition by glibenclamide of the vasorelaxant action of cromakalim in the rat. Br J Pharmacol (1989) 1.52
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol (1987) 1.50
Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet (1983) 1.47
Debendox and congenital malformations in Northern Ireland. Br Med J (1980) 1.46
The biology of ovarian cancer. Semin Oncol (1998) 1.46
A randomized controlled trial of penicillin vs clindamycin for the treatment of aspiration pneumonia in children. Arch Pediatr Adolesc Med (1997) 1.43
Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer (2005) 1.42
Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res (1988) 1.42
Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin Oncol (1984) 1.41
Ovarian cancer biology. Semin Oncol (1991) 1.40
Prostate-specific antigen: problems in analysis. Eur J Cancer (1991) 1.40
Selective concentration and localization of gold in macrophages of synovial and other tissues during and after chrysotherapy in rheumatoid patients. Ann Rheum Dis (1976) 1.40
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res (1997) 1.39
The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res (1998) 1.39
Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer (1981) 1.38
Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res (1984) 1.35
Ultrastructural changes in lung fibroblast cultures exposed to chrysotile asbestos. Br J Exp Pathol (1974) 1.35
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer (1990) 1.35
Metabolism of C19-steroids by foetal cotyledons from the bovine placenta at term. Res Vet Sci (1969) 1.32
Steroid metabolism by human breast tumours. Biochem J (1970) 1.32
Steroid receptors in early breast cancer: value in prognosis. J Steroid Biochem (1981) 1.31
Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res (1988) 1.31
Evidence for a role of adenosine 3',5'-monophosphate in parathyroid hormone release. Endocrinology (1973) 1.30
Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet (1981) 1.29
The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res (2000) 1.27
Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res (1984) 1.25
Quantitative evidence for protein denaturation as the cause of thermal death. Nature (1971) 1.24
Plasma 17OH-progesterone concentrations in newborn infants. Arch Dis Child (1979) 1.24
Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer (1987) 1.23
The binding of tamoxifen to oestrogen receptor proteins under equilibrium and non-equilibrium conditions. Eur J Cancer (1979) 1.23
Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom. Prostate (1997) 1.23
Identification of talc on surgeons' gloves and in tissue from starch granulomas. Br J Surg (1975) 1.22
Medical innumeracy. Lancet (1976) 1.22
Plasma prolactin in breast cancer. Eur J Cancer (1973) 1.22
Ingestion of talc particles by cultured lung fibroblasts. Environ Res (1975) 1.22
Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res (1996) 1.21
Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol (1995) 1.21
The inhibition of deoxyribonucleic acid nucleotidyltransferase by stilboestrol derivatives. Biochem J (1968) 1.20
Internal quality control in clinical chemistry: a teaching review. Stat Med (1987) 1.19
Endocrine treatment in prostate cancer. Semin Surg Oncol (2000) 1.18
Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res (1995) 1.18
A quantitative review of cognitive deficits in depression and Alzheimer-type dementia. J Int Neuropsychol Soc (1997) 1.17
Enhanced peripheral vasodilation in humans after a fatty meal. J Am Coll Cardiol (2000) 1.16
Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab (1975) 1.16
Talc and carcinoma of the ovary and cervix. J Obstet Gynaecol Br Commonw (1971) 1.15
Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res (1994) 1.14
The elemental content of lymphatic tissues of barefooted people in Ethiopia, with reference to endemic elephantiasis of the lower legs. Trans R Soc Trop Med Hyg (1978) 1.12
Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. Cancer Res (1985) 1.12
Survival patterns in hormone treated advanced breast cancer. Br J Surg (1986) 1.12
The benefits of a shared-care prostate clinic. Br J Urol (1996) 1.12
Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst (1989) 1.11
Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res (1993) 1.11
Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer. Int J Cancer (1996) 1.11
Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res (1995) 1.11
Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential. Med Res Rev (1992) 1.11
Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol (1976) 1.10
Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy. Acta Endocrinol (Copenh) (1976) 1.10
The biology of ovarian cancer development. Cancer (1993) 1.10
The effect of some stilboestrol compounds on DNA polymerase from human prostatic tissue. Steroids (1970) 1.09
The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer. Eur J Surg Oncol (1988) 1.09
Steroids in saliva for assessing endocrine function. Endocr Rev (1982) 1.09
Role of adrenergic stimuli in parathyroid hormone secretion in man. J Clin Endocrinol Metab (1975) 1.07
An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. Br J Cancer (1990) 1.07
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol (1996) 1.07
Mechanisms of drug resistance in ovarian cancer. Cancer (1993) 1.06
Disabled-2 mediates c-Fos suppression and the cell growth regulatory activity of retinoic acid in embryonic carcinoma cells. J Biol Chem (2001) 1.05
A simple replication technique for the study of biological tissues by electron microscopy. J Microsc (1969) 1.05
Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact (1998) 1.03
Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res (1991) 1.03
Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res (1994) 1.03
Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res (1994) 1.03